The Cancer Letter

Inside information on cancer research and drug development

ClinicalTrials & Tribulations

Does salpingectomy prevent ovarian cancer? Let’s prove it.

The SOROCk clinical trial, NRG CC008 (NCT04251052)

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

Abstract

The majority of epithelial ovarian cancer is diagnosed at an advanced stage and long-term survival is low. Since ovarian cancer screening is ineffective, the main focus to reduce ovarian cancer mortality is prevention. 

For individuals at increased risk of ovarian carcinoma, risk-reducing bilateral salpingo-oophorectomy (RRSO) is highly effective, but uptake at the recommended age is suboptimal, likely due to concerns about premature menopause. 

Mounting evidence suggests that many “ovarian” cancers originate in the fallopian tube, making bilateral salpingectomy with delayed oophorectomy an attractive, but as of yet, unproven option for risk-reduction in those who decline RRSO. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

YOU MAY BE INTERESTED IN

Guest Editorial

Moving from mandate to mission: Community outreach and engagement at NCI-designated cancer centers
“COE is broken.”

Acting Director Dr. Krzysztof Ptak’s words reverberated throughout the meeting room—and the heads of several of us—during the National Cancer Institute’s Office of Cancer Centers update on the final day of the 2024 Association of American Cancer Institutes/Cancer Center Administrators Forum Annual Meeting in Chicago.
By Monica L. Baskin, Nadine J. Barrett, Kim F. Rhoads, Hayley S. Thompson, Kimlin Tam Ashing, Folakemi T. Odedina and Vanessa B. Sheppard
In Brief

VCU awarded $9M from NCI to establish Cancer Control Equity Research Center

Virginia Commonwealth University has been awarded a five-year, $9 million grant from NCI to establish a pioneering Cancer Control Equity Research Center. This initiative aims to enhance the dissemination and implementation of health promotion and cancer prevention services for individuals and families residing in Virginia’s Housing and Urban Development-administered income-based housing communities in the Greater Richmond region and Hampton Roads.
Byline
Kathryn P. Pennington, MD
Assistant professor, Division of Gynecologic Oncology, University of Washington School of Medicine
Warner K. Huh, MD
Professor & chair, Department of Obstetrics and Gynecology; Division of Gynecologic Oncology, University of Alabama School of Medicine
Sandra Russo, MD, PhD, MPH
Medical officer, Division of Cancer Prevention, National Cancer Institute
Joan L. Walker, MD
Professor, Division of Gynecologic Oncology, Stephenson Cancer Center, Oklahoma University Health Sciences Center
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account